Vertex Pharmaceuticals Incorporated VRTX stock has declined 8.9% in the past three months. The deterioration was due to soft first-quarter results, slower-than-expected uptake of its newer drugs ...

Vertex Pharmaceuticals: 2025 TIME100 Most Influential CompaniesRyan Reynolds is trying to focus on our conversation. But all he can think about is the script pulled up on his laptop. The ...

Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. After a thorough review of the options trading surrounding Vertex Pharmaceuticals, we move ...

Vertex will continue to work with reimbursement bodies across the European Union member states to ensure access for all eligible patients as quickly as possible. Story Continues and ...

Vertex stem cell therapy spurs insulin independence Sandy Huffaker for STAT By Meghana Keshavan June 23, 2025 Biotech Correspondent ...

RI HEALTH Vertex to lay off 125 employees in R.I., consolidate offices The layoffs will be effective on Aug. 5, according to a letter sent to the state’s Department of Labor and Training ...

Contacts Vertex Pharmaceuticals Incorporated Investors: [email protected] Media: [email protected] or International: +44 20 3204 5275 or U.S.: 617-341-6992 or Heather Nichols: +1 617-839-3607 ...

Vertex Pharmaceuticals (VRTX) stock in focus as the company updates data from a Phase 1/2/3 trial for its experimental type 1 diabetes drug zimislecel. Read more here.

In trading on Friday, shares of Vertex Inc (Symbol: VERX) entered into oversold territory, hitting an RSI reading of 27.8, after changing hands as low as $34.1938 per share.